share_log

Alnylam Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Alnylam Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

阿里拉姆制藥 | 10-Q：2024財年二季報
美股SEC公告 ·  08/01 20:26

Moomoo AI 已提取核心訊息

Alnylam Pharmaceuticals reported robust Q2 2024 financial results, with total revenues of $659.8 million, up 107% year-over-year. Net product revenues reached $410.1 million, driven by strong growth of AMVUTTRA. The company achieved a milestone in its HELIOS-B trial for ATTR amyloidosis with cardiomyopathy, planning global regulatory filings later this year.Research and development expenses increased to $294.1 million, reflecting investments in preclinical activities and clinical trials for zilebesiran and mivelsiran. Selling, general and administrative expenses rose to $248.4 million due to increased marketing efforts for TTR therapies. The company reported a net loss of $16.9 million for the quarter.Alnylam advanced its pipeline with positive results from the KARDIA-2 study of zilebesiran for hypertension and initiated the KARDIA-3 trial. The company also dosed the first patient in the cAPPRicorn-1 Phase 2 trial of mivelsiran for cerebral amyloid angiopathy. With $42.6 million in net cash provided by operating activities, Alnylam believes its current financial position is sufficient to fund operations for at least the next 12 months.
Alnylam Pharmaceuticals reported robust Q2 2024 financial results, with total revenues of $659.8 million, up 107% year-over-year. Net product revenues reached $410.1 million, driven by strong growth of AMVUTTRA. The company achieved a milestone in its HELIOS-B trial for ATTR amyloidosis with cardiomyopathy, planning global regulatory filings later this year.Research and development expenses increased to $294.1 million, reflecting investments in preclinical activities and clinical trials for zilebesiran and mivelsiran. Selling, general and administrative expenses rose to $248.4 million due to increased marketing efforts for TTR therapies. The company reported a net loss of $16.9 million for the quarter.Alnylam advanced its pipeline with positive results from the KARDIA-2 study of zilebesiran for hypertension and initiated the KARDIA-3 trial. The company also dosed the first patient in the cAPPRicorn-1 Phase 2 trial of mivelsiran for cerebral amyloid angiopathy. With $42.6 million in net cash provided by operating activities, Alnylam believes its current financial position is sufficient to fund operations for at least the next 12 months.
阿里拉姆制藥報告了強勁的2024年第二季度財務結果，總收入達65980萬美元，同比增長107%。淨產品收入達到41010萬美元，主要受到AMVUTTRA強勁增長的推動。公司在其針對心肌病的ATTR澱粉樣變性HELIOS-b試驗中取得了一個里程碑，計劃在今年晚些時候提交全球監管申請。研發費用增加至29410萬美元，反映了對zilebesiran和mivelsiran的前臨牀活動和臨牀試驗的投資。由於對TTR療法的營銷力度增加，銷售、一般和行政費用上升至24840萬美元。公司報告本季度淨虧損爲1690萬美元。阿里拉姆推進了其項目管道，zilebesiran用於高血壓的KARDIA-2研究結果積極，並啓動了KARDIA-3試驗。公司還在mivelsiran針對腦澱粉樣血管病的cAPPRicorn-1二期試驗中給第一名患者用藥。憑藉4260萬美元的運營活動淨現金，阿里拉姆認爲其當前的財務狀況足以支持至少未來12個月的運營。
阿里拉姆制藥報告了強勁的2024年第二季度財務結果，總收入達65980萬美元，同比增長107%。淨產品收入達到41010萬美元，主要受到AMVUTTRA強勁增長的推動。公司在其針對心肌病的ATTR澱粉樣變性HELIOS-b試驗中取得了一個里程碑，計劃在今年晚些時候提交全球監管申請。研發費用增加至29410萬美元，反映了對zilebesiran和mivelsiran的前臨牀活動和臨牀試驗的投資。由於對TTR療法的營銷力度增加，銷售、一般和行政費用上升至24840萬美元。公司報告本季度淨虧損爲1690萬美元。阿里拉姆推進了其項目管道，zilebesiran用於高血壓的KARDIA-2研究結果積極，並啓動了KARDIA-3試驗。公司還在mivelsiran針對腦澱粉樣血管病的cAPPRicorn-1二期試驗中給第一名患者用藥。憑藉4260萬美元的運營活動淨現金，阿里拉姆認爲其當前的財務狀況足以支持至少未來12個月的運營。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間